SequelSEC

Kraig Biocraft Laboratories, Inc. KBLB

Plastic Material, Synth Resin/Rubber, Cellulos (No Glass) · CIK 0001413119 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2021-06-30
Operating income
-$705.18K
Fiscal year ended 2021-06-30
Free cash flow
Unavailable
Fiscal year ended 2021-06-30

Kraig Biocraft Laboratories, Inc. (KBLB) reported revenue of $0 and net income of -$2.75M for the fiscal year ended 2021-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Kraig Biocraft Laboratories, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Plastic Material, Synth Resin/Rubber, Cellulos (No Glass).

Income

Kraig Biocraft Laboratories, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-06-302020-06-302019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
Revenue$0$0$0$0$0$0$140.76K$152.23K$108.63K$70.10K
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$705.18K-$470.33K-$1.06M-$335.24K-$412.01K-$432.52K-$147.95K-$152.93K-$226.56K-$251.07K
Net income-$2.75M-$568.80K-$1.13M-$402.50K-$477.75K-$494.48K-$206.98K-$188.59K-$278.93K-$298.83K
Research & development$44.73K$32.97K$43.99K$20.94K$22.30K$56.83K$20.22K$50.89K$20.13K$67.90K
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income-$2.75M-$568.80K-$1.13M-$402.50K-$477.75K-$494.48K-$206.98K-$188.59K-$278.93K-$298.83K
Income tax expenseUnavailableUnavailable$0$0$0$0$0$0$0$0
Diluted EPSUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$369.31K$348.28K$826.57K$122.19K$117.97K$111.23K$123.70K$99.29K$181.65K$95.24K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Kraig Biocraft Laboratories, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-06-302020-06-302019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
Cash & equivalentsUnavailableUnavailable$283.15K$674.23K$907.65K$13.70K$22.34K$34.44K$48.52K$18.15K
Total assets$4.09M$586.15K$898.61K$1.28M$1.11M$71.38K$180.61K$213.44K$159.85K$114.50K
Current assets$3.67M$63.18K$295.82K$709.47K$912.80K$20.56K$122.96K$152.90K$93.98K$48.49K
Total liabilities$9.10M$6.90M$5.50M$5.34M$4.76M$4.53MUnavailableUnavailableUnavailableUnavailable
Current liabilities$8.75M$6.44M$4.90M$4.70M$4.42M$4.53M$4.15M$3.98M$3.74M$3.49M
Total equity incl. NCI-$5.02M-$6.31M-$4.61M-$4.07M-$3.65M-$4.46M-$3.97M-$3.76M-$3.58M-$3.38M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$99.26K$114.00K$40.99K$25.87K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

Kraig Biocraft Laboratories, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-06-302020-06-302019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
Operating cash flowUnavailableUnavailable-$314.11K-$230.42K-$225.05K-$65.64K-$28.21K-$62.78K-$78.37K-$79.27K
Capital expendituresUnavailableUnavailable$72.97K$0$0$0$3.89K$1.30K$6.26K$7.00K
Investing cash flowUnavailableUnavailable-$72.97K$0$0$0-$3.89K-$1.30K-$6.26K-$7.00K
Financing cash flowUnavailableUnavailable-$4.00K-$3.00K$1.12M$57.00K$20.00K$50.00K$115.00K$30.00K
Net change in cashUnavailableUnavailable-$391.08K-$233.42K$893.95K-$8.64K-$12.10K-$14.09K$30.37K-$56.27K
Stock-based compensationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailable$9.04K$6.74K$6.66K$6.82K$6.77K$6.64K$6.40K$6.17K

Derived

Kraig Biocraft Laboratories, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-06-302020-06-302019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
Free cash flowUnavailableUnavailable-$387.08KUnavailableUnavailable-$65.64K-$32.10K-$64.09K-$84.63K-$86.27K
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-105.1%-100.5%-208.6%-358.2%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-22.8%-42.1%-77.9%-123.1%
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio0.42x0.01x0.06x0.15x0.21x0.00x0.03x0.04x0.03x0.01x
Revenue YoY growthUnavailableUnavailable-100.0%-100.0%-100.0%-100.0%417.1%UnavailableUnavailable431.6%
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-147.0%-123.9%-256.8%-426.3%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable14.4%33.4%18.5%96.9%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable2.8%0.9%5.8%10.0%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open KBLB in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.